Keeping HIV a Priority, PEPFAR Funding and Pricing | AIDS 2024
Juan Michael Porter II, a prominent healthcare journalist and HIV advocate, spoke to MHE about keeping HIV/AIDS a priority and the dynamics of funding programs and pharmaceutical pricing
Second of two parts
Juan Michael Porter II, a senior editor at TheBody.com and co-host of the International AIDS Society's (IAS) podcast, "HIV Unmuted," moderated a session on the future of HIV/AIDs science at IAS 2024 AIDS meeting this week in Munich, Germany.
In a video interview with Managed Healthcare Executive recorded before the meeting, Porter discussed the prospect of cuts in the funding of HIV treatment and prevention programs, particularly the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Porter referenced arguments made by Francoise Barre-Sinoussi, who was part of the team that won a Nobel Prize for identifying HIV as the cause of AIDS, that links funding issues to linked to prices set by pharmaceutical companies. Porter also expressed trust that Jeanne Marrazzo, M.D., M.P.H., director of the National Institute of Allergy and Infectious Diseases would keep HIV/AIDS a priority.
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
With PrEP Effort Lagging, Positive Results for Twice-Yearly Lenacapavir May Give a Lift | AIDS 2024
July 25th 2024Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.
Read More
